Aktienanalyse zu Senti Biosciences Holdings Inc (SNTI)SNTISenti Biosciences Holdings Inc

Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Senti Biosciences Inc is not a good buy right now due to significant financial losses and a very low RSI of 15.912, indicating oversold conditions. The company has reported a staggering year-to-date change of -82.87% and a one-year change of -91.59%, which reflects severe underperformance. The latest earnings report shows a Q1 2026 EPS of -0.14 and a revenue of only $0.01 million, raising concerns about its ability to generate income. Furthermore, the current price is $0.19, which is far below its historical highs, suggesting a lack of investor confidence and potential for further declines. The main risk is the ongoing operational losses, with a net income loss of -$12.75 million in Q2 2026, which could lead to liquidity issues and further stock depreciation.